NO20020925L - N-heterosykliske derivater av NOS-inhibitorer - Google Patents

N-heterosykliske derivater av NOS-inhibitorer

Info

Publication number: NO20020925L
Authority: NO; Norway
Prior art keywords: heterocyclic derivatives; nos inhibitors; inhibitors; compounds; nitric oxide
Prior art date: 1999-08-26

Application number

NO20020925A

Other languages

English (en)

Other versions

NO20020925D0 (no

NO323886B1 (no

Inventor

Damian O Arnaiz

John J Baldwin

David D Davey

James J Devlin

Iii Roland Ellwood Dolle

Shawn David Erickson

Kirk Mcmillan

Michael M Morrissey

Michael H J Ohlmeyer

Gonghua Pan

Vidyadhar Madhav Paradkar

John Parkinson

Gary B Phillips

Bin Ye

Zuchun Zhao

Original Assignee

Pharmacopeia Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-26

Filing date

2002-02-26

Publication date

2002-04-16

2002-02-26 Application filed by Pharmacopeia Inc filed Critical Pharmacopeia Inc

2002-02-26 Publication of NO20020925D0 publication Critical patent/NO20020925D0/no

2002-04-16 Publication of NO20020925L publication Critical patent/NO20020925L/no

2007-07-16 Publication of NO323886B1 publication Critical patent/NO323886B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Psychology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20020925A 1999-08-26 2002-02-26 N-heterosykliske derivater av NOS-inhibitorer, farmasoytisk preparat inneholdende disse, og deres anvendelse for fremstilling av medikament. NO323886B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/383,813 US6432947B1 (en)	1997-02-19	1999-08-26	N-heterocyclic derivatives as NOS inhibitors
PCT/US2000/023173 WO2001014371A1 (en)	1999-08-26	2000-08-24	N-heterocyclic derivatives as nos inhibitors

Publications (3)

Publication Number	Publication Date
NO20020925D0 NO20020925D0 (no)	2002-02-26
NO20020925L true NO20020925L (no)	2002-04-16
NO323886B1 NO323886B1 (no)	2007-07-16

Family

ID=23514822

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20020925A NO323886B1 (no)	1999-08-26	2002-02-26	N-heterosykliske derivater av NOS-inhibitorer, farmasoytisk preparat inneholdende disse, og deres anvendelse for fremstilling av medikament.

Country Status (34)

Country	Link
US (11)	US6432947B1 (no)
EP (1)	EP1206467B1 (no)
JP (1)	JP4739625B2 (no)
KR (1)	KR100708783B1 (no)
CN (1)	CN1206228C (no)
AT (1)	ATE256681T1 (no)
AU (1)	AU769405B2 (no)
BG (1)	BG65804B1 (no)
BR (1)	BR0014144A (no)
CA (1)	CA2376355C (no)
CZ (1)	CZ2002642A3 (no)
DE (1)	DE60007329T2 (no)
DK (1)	DK1206467T3 (no)
EE (1)	EE05199B1 (no)
ES (1)	ES2213599T3 (no)
HK (1)	HK1043594A1 (no)
HR (1)	HRP20020175B1 (no)
HU (1)	HUP0202450A3 (no)
IL (2)	IL148313A0 (no)
LT (1)	LT4982B (no)
LV (1)	LV12887B (no)
MX (1)	MXPA02002022A (no)
NO (1)	NO323886B1 (no)
NZ (1)	NZ517411A (no)
PL (1)	PL353539A1 (no)
PT (1)	PT1206467E (no)
RO (1)	RO122202B1 (no)
RS (1)	RS50378B (no)
RU (1)	RU2277094C2 (no)
SI (1)	SI20818B (no)
SK (1)	SK2622002A3 (no)
UA (1)	UA72930C2 (no)
WO (1)	WO2001014371A1 (no)
ZA (1)	ZA200201485B (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6432947B1 (en) *	1997-02-19	2002-08-13	Berlex Laboratories, Inc.	N-heterocyclic derivatives as NOS inhibitors
HRP990246A2 (en)	1998-08-07	2000-06-30	Du Pont Pharm Co	Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ509241A (en)	1998-08-07	2003-08-29	Du Pont Pharm Co	Succinoylamino lactams as inhibitors of alpha-beta protein production
AU777735B2 (en) *	1999-07-15	2004-10-28	Pharmacopeia, Inc.	Bradykinin B1 receptor antagonists
GB2361473C (en) *	2000-03-08	2005-06-28	Microgenics Corp	Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
JP2003535046A (ja)	2000-04-03	2003-11-25	デュポンファーマシューティカルズカンパニー	Ａβタンパク質産生の阻害剤としての環状ラクタム
US20030055249A1 (en) *	2001-07-17	2003-03-20	Fick David B.	Synthesis and methods of use of pyrimidine analogues and derivatives
US7885709B2 (en) *	2001-08-31	2011-02-08	Bio Control Medical (B.C.M.) Ltd.	Nerve stimulation for treating disorders
US8571653B2 (en) *	2001-08-31	2013-10-29	Bio Control Medical (B.C.M.) Ltd.	Nerve stimulation techniques
US7904176B2 (en)	2006-09-07	2011-03-08	Bio Control Medical (B.C.M.) Ltd.	Techniques for reducing pain associated with nerve stimulation
US7778711B2 (en) *	2001-08-31	2010-08-17	Bio Control Medical (B.C.M.) Ltd.	Reduction of heart rate variability by parasympathetic stimulation
EP1795192A3 (en) *	2002-04-30	2008-05-07	Bayer Schering Pharma Aktiengesellschaft	1-(Pyridazin-3-yl)-imidazole derivatives as inhibitors of nitric oxide synthase (NOS)
US6982259B2 (en) *	2002-04-30	2006-01-03	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors
AU2003260033A1 (en) *	2002-08-29	2004-03-19	Schering Aktiengesellschaft	Methods of treating acute respiratory distress syndrome
JP2006506366A (ja) *	2002-10-18	2006-02-23	ファイザー・プロダクツ・インク	カンナビノイド受容体リガンドおよびその使用方法
AU2005214319B2 (en) *	2004-02-12	2009-02-19	Merck Sharp & Dohme Corp.	Amino heterocyclic modulators of chemokine receptor activity
EP1568698A1 (en) *	2004-02-27	2005-08-31	Aventis Pharma Deutschland GmbH	Pyrrole-derivatives as factor Xa inhibitors
KR100935273B1 (ko) *	2004-06-10	2010-01-06	아이알엠 엘엘씨	단백질 키나제 억제제 화합물 및 조성물
BRPI0511978A (pt) *	2004-06-10	2008-01-22	Irm Llc	compostos e composições como inibidores de proteìnas quinases
US7622486B2 (en) *	2004-09-23	2009-11-24	Reddy Us Therapeutics, Inc.	Pyridine compounds, process for their preparation and compositions containing them
UY29177A1 (es) *	2004-10-25	2006-05-31	Astex Therapeutics Ltd	Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) *	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006055831A2 (en) *	2004-11-17	2006-05-26	Miikana Therapeutics, Inc.	Kinase inhibitors
US20070123572A1 (en) *	2005-11-28	2007-05-31	Kalypsys, Inc.	Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines
EP1817030A2 (en) *	2004-12-01	2007-08-15	Kalypsys, Inc.	Inducible nitric oxide synthase dimerization inhibitors
KR101155335B1 (ko) *	2005-01-07	2012-06-11	엘지전자 주식회사	이동통신 단말기의 멀티미디어 메시지 동작방법
JP2008534689A (ja) *	2005-04-05	2008-08-28	ファーマコペイア，インコーポレイテッド	免疫抑制のためのプリン及びイミダゾピリジン誘導体
US7884109B2 (en) *	2005-04-05	2011-02-08	Wyeth Llc	Purine and imidazopyridine derivatives for immunosuppression
EP1923388A4 (en)	2005-08-12	2011-03-09	Takeda Pharmaceutical	BRAIN / NEURONAL CELL PROTECTIVE AGENT AND THERAPEUTIC AGENT FOR SLEEP DISORDERS
EP1928456B1 (en) *	2005-09-30	2015-04-22	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
EP1954694A1 (en) *	2005-11-28	2008-08-13	Kalypsys, Inc.	Imidazole derivatives as nitric oxide synthase dimerisation inhibitor
US7989459B2 (en) *	2006-02-17	2011-08-02	Pharmacopeia, Llc	Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20090281075A1 (en) *	2006-02-17	2009-11-12	Pharmacopeia, Inc.	Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US8017612B2 (en) *	2006-04-18	2011-09-13	Japan Tobacco Inc.	Piperazine compound and use thereof as a HCV polymerase inhibitor
US20090124610A1 (en) *	2006-04-25	2009-05-14	Gordon Saxty	Pharmaceutical compounds
EP3719018B1 (en) *	2006-04-25	2025-08-27	Astex Therapeutics Ltd	Purine and deazapurine derivatives as pharmaceutical compounds
PT3146982T (pt)	2006-10-03	2019-10-31	Genzyme Corp	Terapia génica para esclerose lateral amiotrófica e outros distúrbios da medula espinal
US7902187B2 (en) *	2006-10-04	2011-03-08	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
CL2007002866A1 (es) *	2006-10-04	2008-07-04	Pharmacopeia Inc	Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
WO2008043019A1 (en) *	2006-10-04	2008-04-10	Pharmacopeia, Inc	8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
US20080119496A1 (en) *	2006-11-16	2008-05-22	Pharmacopeia Drug Discovery, Inc.	7-Substituted Purine Derivatives for Immunosuppression
EP1939181A1 (en) *	2006-12-27	2008-07-02	sanofi-aventis	Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
CA2683152A1 (en) *	2007-06-11	2008-12-18	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
NZ585261A (en)	2007-10-11	2011-10-28	Astrazeneca Ab	Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
JP2011510998A (ja) *	2008-01-30	2011-04-07	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	新規ｓＥＨ阻害剤およびその使用
WO2009097474A1 (en) *	2008-01-30	2009-08-06	Smithkline Beecham Corporation	Novel seh inhibitors and their use
WO2009097475A1 (en) *	2008-01-30	2009-08-06	Smithkline Beecham Corporation	NOVEL sEH INHIBITORS AND THEIR USE
US20110053907A1 (en) *	2008-03-27	2011-03-03	Auckland Uniservices Limited	Substituted pyrimidines and triazines and their use in cancer therapy
GB0908394D0 (en)	2009-05-15	2009-06-24	Univ Leuven Kath	Novel viral replication inhibitors
GB0913636D0 (en)	2009-08-05	2009-09-16	Univ Leuven Kath	Novel viral replication inhibitors
BR112012006130A2 (pt)	2009-09-18	2016-06-28	Volvo Lastvagnar Ab	console para atamento para um chassi de veículo e veículo compreendendo um console de transporte de suspensão.
EP2640705A2 (en)	2010-11-15	2013-09-25	Katholieke Universiteit Leuven	Novel antiviral compounds
CN102617503B (zh) *	2011-03-03	2014-05-07	上海常丰生物医药科技有限公司	(s)-3-吗啉基羧酸的合成方法
ME03589B (me)	2011-04-01	2020-07-20	Astrazeneca Ab	Terapeutski tretman
PT2785349T (pt)	2011-11-30	2019-12-11	Astrazeneca Ab	Tratamento combinado de cancro
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
US9701661B2 (en) *	2014-07-11	2017-07-11	Northwestern University	2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
GB201512635D0 (en)	2015-07-17	2015-08-26	Ucl Business Plc	Uses of therapeutic compounds
AU2017384388B2 (en)	2016-12-20	2020-09-17	Astrazeneca Ab	Amino-triazolopyridine compounds and their use in treating cancer
CN107115334A (zh) *	2017-03-04	2017-09-01	王宏	一种治疗免疫性流产的药物组合物
IL277495B2 (en)	2018-03-23	2024-08-01	Carmot Therapeutics Inc	Modulators of protein-coupled receptors - G
EP3628669A1 (en)	2018-09-28	2020-04-01	GenKyoTex Suisse SA	Novel compounds as nadph oxidase inhibitors
EP4337682A2 (en)	2021-05-13	2024-03-20	Carmot Therapeutics Inc.	Modulators of g-protein coupled receptors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6339875A (ja)	1986-08-05	1988-02-20	Nissin Food Prod Co Ltd	ピリミジン誘導体
DE4118720A1 (de)	1991-06-07	1992-12-10	Bayer Ag	Substituierte imidazolinylpyrimidine
TW212798B (no) *	1991-11-25	1993-09-11	Takeda Pharm Industry Co Ltd
WO1993017009A1 (fr) *	1992-02-28	1993-09-02	Zenyaku Kogyo Kabushiki Kaisha	DERIVE DE s-TRIAZINE ET REMEDE CONTRE DES MALADIES DEPENDENTES DE L'×STROGENE LE CONTENANT COMME INGREDIENT ACTIF
TW279864B (no) *	1993-02-19	1996-07-01	Janssen Pharmaceutica Nv
US5593992A (en)	1993-07-16	1997-01-14	Smithkline Beecham Corporation	Compounds
ES2114662T3 (es)	1993-08-26	1998-06-01	Ono Pharmaceutical Co	Derivados de la 4-aminopirimidina.
US5426110A (en)	1993-10-06	1995-06-20	Eli Lilly And Company	Pyrimidinyl-glutamic acid derivatives
US5629322A (en)	1994-11-15	1997-05-13	Merck & Co., Inc.	Cyclic amidine analogs as inhibitors of nitric oxide synthase
WO1996014842A1 (en)	1994-11-15	1996-05-23	Merck & Co., Inc.	Substituted heterocycles as inhibitors of nitric oxide synthase
US7091346B1 (en) *	1995-11-01	2006-08-15	Novartis Ag	Purine derivatives and processes for their preparation
ZA977427B (en)	1996-09-04	1998-03-02	Dainippon Pharmaceutical Co	2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same.
US6432947B1 (en) *	1997-02-19	2002-08-13	Berlex Laboratories, Inc.	N-heterocyclic derivatives as NOS inhibitors
PL335235A1 (en) *	1997-02-19	2000-04-10	Berlex Lab	N-heterocyclic derivatives as nos inhibitors
AU725548B2 (en) *	1997-03-11	2000-10-12	E.I. Du Pont De Nemours And Company	Heteroaryl azole herbicides
US6525051B2 (en)	2000-03-27	2003-02-25	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors

1999
- 1999-08-26 US US09/383,813 patent/US6432947B1/en not_active Expired - Fee Related
2000
- 2000-08-24 IL IL14831300A patent/IL148313A0/xx active IP Right Grant
- 2000-08-24 BR BR0014144-5A patent/BR0014144A/pt not_active Application Discontinuation
- 2000-08-24 SI SI200020040A patent/SI20818B/sl not_active IP Right Cessation
- 2000-08-24 JP JP2001518702A patent/JP4739625B2/ja not_active Expired - Fee Related
- 2000-08-24 RS YUP-120/02A patent/RS50378B/sr unknown
- 2000-08-24 DK DK00959333T patent/DK1206467T3/da active
- 2000-08-24 UA UA2002032401A patent/UA72930C2/uk unknown
- 2000-08-24 HK HK02105317.3A patent/HK1043594A1/zh unknown
- 2000-08-24 RU RU2002107203/04A patent/RU2277094C2/ru not_active IP Right Cessation
- 2000-08-24 CZ CZ2002642A patent/CZ2002642A3/cs unknown
- 2000-08-24 NZ NZ517411A patent/NZ517411A/en unknown
- 2000-08-24 EP EP00959333A patent/EP1206467B1/en not_active Expired - Lifetime
- 2000-08-24 CA CA002376355A patent/CA2376355C/en not_active Expired - Fee Related
- 2000-08-24 HR HR20020175A patent/HRP20020175B1/xx not_active IP Right Cessation
- 2000-08-24 PL PL00353539A patent/PL353539A1/xx not_active Application Discontinuation
- 2000-08-24 AU AU70671/00A patent/AU769405B2/en not_active Ceased
- 2000-08-24 RO ROA200200205A patent/RO122202B1/ro unknown
- 2000-08-24 HU HU0202450A patent/HUP0202450A3/hu unknown
- 2000-08-24 WO PCT/US2000/023173 patent/WO2001014371A1/en not_active Ceased
- 2000-08-24 KR KR1020027002407A patent/KR100708783B1/ko not_active Expired - Fee Related
- 2000-08-24 EE EEP200200091A patent/EE05199B1/xx not_active IP Right Cessation
- 2000-08-24 SK SK262-2002A patent/SK2622002A3/sk unknown
- 2000-08-24 ES ES00959333T patent/ES2213599T3/es not_active Expired - Lifetime
- 2000-08-24 MX MXPA02002022A patent/MXPA02002022A/es active IP Right Grant
- 2000-08-24 CN CNB008146691A patent/CN1206228C/zh not_active Expired - Fee Related
- 2000-08-24 DE DE60007329T patent/DE60007329T2/de not_active Expired - Lifetime
- 2000-08-24 AT AT00959333T patent/ATE256681T1/de not_active IP Right Cessation
- 2000-08-24 PT PT00959333T patent/PT1206467E/pt unknown
2002
- 2002-02-21 ZA ZA200201485A patent/ZA200201485B/en unknown
- 2002-02-21 IL IL148313A patent/IL148313A/en not_active IP Right Cessation
- 2002-02-26 BG BG106440A patent/BG65804B1/bg unknown
- 2002-02-26 NO NO20020925A patent/NO323886B1/no not_active IP Right Cessation
- 2002-03-15 LT LT2002028A patent/LT4982B/lt not_active IP Right Cessation
- 2002-03-26 LV LVP-02-50A patent/LV12887B/en unknown
- 2002-04-12 US US10/121,808 patent/US6670473B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,886 patent/US6841673B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/122,006 patent/US6864368B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,212 patent/US6849739B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,758 patent/US6846829B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,682 patent/US20030073669A1/en not_active Abandoned
- 2002-04-12 US US10/121,379 patent/US6747031B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/122,072 patent/US6841674B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/122,047 patent/US6887865B2/en not_active Expired - Fee Related
- 2002-04-12 US US10/121,659 patent/US6864263B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6864368B2 (en)	2005-03-08
US20030060452A1 (en)	2003-03-27
WO2001014371A1 (en)	2001-03-01
NO20020925D0 (no)	2002-02-26
CN1382136A (zh)	2002-11-27
SK2622002A3 (en)	2002-09-10
US20020183323A1 (en)	2002-12-05
LT2002028A (en)	2002-09-25
HUP0202450A3 (en)	2003-12-29
IL148313A0 (en)	2002-09-12
ZA200201485B (en)	2003-07-30
IL148313A (en)	2008-04-13
US6747031B2 (en)	2004-06-08
CN1206228C (zh)	2005-06-15
US20030092678A1 (en)	2003-05-15
ATE256681T1 (de)	2004-01-15
AU769405B2 (en)	2004-01-29
SI20818A (sl)	2002-08-31
CA2376355C (en)	2009-10-27
HK1051683A1 (en)	2003-08-15
RO122202B1 (ro)	2009-02-27
PT1206467E (pt)	2004-05-31
JP4739625B2 (ja)	2011-08-03
US20030073669A1 (en)	2003-04-17
HRP20020175A2 (en)	2005-10-31
US6846829B2 (en)	2005-01-25
US6864263B2 (en)	2005-03-08
US6841673B2 (en)	2005-01-11
US20020165203A1 (en)	2002-11-07
EP1206467B1 (en)	2003-12-17
US20030004137A1 (en)	2003-01-02
HRP20020175B1 (hr)	2008-07-31
DE60007329D1 (de)	2004-01-29
US6841674B2 (en)	2005-01-11
LV12887B (en)	2003-01-20
US6887865B2 (en)	2005-05-03
US6849739B2 (en)	2005-02-01
US20030027794A1 (en)	2003-02-06
UA72930C2 (uk)	2005-05-16
US20030069210A1 (en)	2003-04-10
DK1206467T3 (da)	2004-04-26
CZ2002642A3 (cs)	2002-08-14
NZ517411A (en)	2003-09-26
BG106440A (en)	2002-11-29
RU2277094C2 (ru)	2006-05-27
ES2213599T3 (es)	2004-09-01
KR20020062277A (ko)	2002-07-25
JP2003507476A (ja)	2003-02-25
DE60007329T2 (de)	2004-06-09
NO323886B1 (no)	2007-07-16
AU7067100A (en)	2001-03-19
US20030083332A1 (en)	2003-05-01
CA2376355A1 (en)	2001-03-01
LT4982B (lt)	2003-01-27
US6432947B1 (en)	2002-08-13
RS50378B (sr)	2009-11-10
EP1206467A1 (en)	2002-05-22
YU12002A (sh)	2005-03-15
SI20818B (sl)	2009-04-30
PL353539A1 (en)	2003-12-01
HUP0202450A2 (hu)	2002-11-28
EE05199B1 (et)	2009-08-17
US6670473B2 (en)	2003-12-30
US20030078265A1 (en)	2003-04-24
HK1043594A1 (zh)	2002-09-20
EE200200091A (et)	2003-04-15
BR0014144A (pt)	2002-05-21
MXPA02002022A (es)	2002-10-31
BG65804B1 (bg)	2009-12-31
KR100708783B1 (ko)	2007-04-19

Publication	Publication Date	Title
NO20020925L (no)	2002-04-16	N-heterosykliske derivater av NOS-inhibitorer
DK0968206T3 (da)	2007-03-26	N-heterocykliske derivater som NOS-inhibitorer
DK1268471T3 (da)	2004-02-09	N-heterocykliske derivater som NOS-inhibitorer
DE60311646D1 (de)	2007-03-22	1-substituierten imidazol derivaten als nos inhibitoren
ATE300541T1 (de)	2005-08-15	Pyrazolopyridinderivate
IL173810A0 (en)	2006-07-05	Imidazopyridine derivatives and pharmaceutical compositions containing the same
AU2002248531A1 (en)	2002-09-24	Pyrazolopyriadine derivatives
SE9904128D0 (sv)	1999-11-15	Novel compounds
IL173895A0 (en)	2006-07-05	Imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2004093796A3 (en)	2005-09-09	Lactam derivatives and methods of their use

Legal Events

Date	Code	Title	Description
2011-04-04	MM1K	Lapsed by not paying the annual fees